Needham analyst Ami Fadia downgraded Intra-Cellular (ITCI) to Hold from Buy without a price target after Johnson & Johnson said will acquire all outstanding shares of Intra-Cellular for a payment of $132.00 per share in cash.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITCI:
- Intra-Cellular downgraded to Equal Weight from Overweight at Morgan Stanley
- Morning Movers: Intra-Cellular surges following deal to be bought by J&J
- Johnson & Johnson to Acquire Intra-Cellular Therapies
- M&A News: Intra-Cellular Stock Rallies 36% on News of $14.6B Acquisition by Johnson & Johnson
- Johnson & Johnson to acquire Intra-Cellular for $132.00 per share in cash